These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 29028366)
1. Synthesis, modeling and biological evaluation of hybrids from pyrazolo[1,5c]pyrimidine as antileishmanial agents. Atta KFM; Ibrahim TM; Farahat OOM; Al-Shargabi TQ; Marei MG; Bekhit AA; El Ashry ESH Future Med Chem; 2017 Oct; 9(16):1913-1929. PubMed ID: 29028366 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, molecular modeling and biological screening of some pyrazole derivatives as antileishmanial agents. Bekhit AA; Saudi MN; Hassan AM; Fahmy SM; Ibrahim TM; Ghareeb D; El-Seidy AM; Al-Qallaf SM; Habib HJ; Bekhit AEA Future Med Chem; 2018 Oct; 10(19):2325-2344. PubMed ID: 30215271 [TBL] [Abstract][Full Text] [Related]
3. Study of antileishmanial activity of 2-aminobenzoyl amino acid hydrazides and their quinazoline derivatives. Khattab SN; Haiba NS; Asal AM; Bekhit AA; Guemei AA; Amer A; El-Faham A Bioorg Med Chem Lett; 2017 Feb; 27(4):918-921. PubMed ID: 28087274 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and in vitro biological evaluation of novel thiazolopyrimidine derivatives as antileishmanial compounds. Istanbullu H; Bayraktar G; Akbaba H; Cavus I; Coban G; Debelec Butuner B; Kilimcioglu AA; Ozbilgin A; Alptuzun V; Erciyas E Arch Pharm (Weinheim); 2020 Aug; 353(8):e1900325. PubMed ID: 32484266 [TBL] [Abstract][Full Text] [Related]
5. Structure based medicinal chemistry-driven strategy to design substituted dihydropyrimidines as potential antileishmanial agents. Rashid U; Sultana R; Shaheen N; Hassan SF; Yaqoob F; Ahmad MJ; Iftikhar F; Sultana N; Asghar S; Yasinzai M; Ansari FL; Qureshi NA Eur J Med Chem; 2016 Jun; 115():230-44. PubMed ID: 27017551 [TBL] [Abstract][Full Text] [Related]
6. Dihydropyrido[2,3-d]pyrimidines as a new class of antileishmanial agents. Agarwal A; Ramesh ; Ashutosh ; Goyal N; Chauhan PM; Gupta S Bioorg Med Chem; 2005 Dec; 13(24):6678-84. PubMed ID: 16126395 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of aryl pyrimidine derivatives as potential leishmanicidal agents. Suryawanshi SN; Kumar S; Shivahare R; Pandey S; Tiwari A; Gupta S Bioorg Med Chem Lett; 2013 Sep; 23(18):5235-8. PubMed ID: 23910597 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and antileishmanial activity of some 1- or 2-(dihydroxyalkyl) and 3-(dihydroxyalkoxy)pyrazolo [3,4-d] pyrimidines. Gatta F; Gradoni L; Lupardini E; Gramiccia M; Orsini S Farmaco; 1991 Jan; 46(1):75-84. PubMed ID: 2054043 [TBL] [Abstract][Full Text] [Related]
9. A Molecular Modeling Approach to Identify Potential Antileishmanial Compounds Against the Cell Division Cycle (cdc)-2-Related Kinase 12 (CRK12) Receptor of Broni E; Kwofie SK; Asiedu SO; Miller WA; Wilson MD Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33803906 [TBL] [Abstract][Full Text] [Related]
10. In silico study and in vitro antileishmanial and antitrypanosomal evaluation of azopyrazoles and azopyrimidines. Am Alkhaldi A; F Lamie P; A Abdelgawad M Pak J Pharm Sci; 2024 Jan; 37(1(Special)):173-184. PubMed ID: 38747267 [TBL] [Abstract][Full Text] [Related]
11. Biological Evaluation and Molecular Docking with In Silico Physicochemical, Pharmacokinetic and Toxicity Prediction of Pyrazolo[1,5- Naglah AM; Askar AA; Hassan AS; Khatab TK; Al-Omar MA; Bhat MA Molecules; 2020 Mar; 25(6):. PubMed ID: 32245177 [TBL] [Abstract][Full Text] [Related]
12. New 5-(nitroheteroaryl)-1,3,4-thiadiazols containing acyclic amines at C-2: synthesis and SAR study for their antileishmanial activity. Tahghighi A; Emami S; Razmi S; Rezazade Marznaki F; Kabudanian Ardestani S; Dastmalchi S; Kobarfard F; Shafiee A; Foroumadi A J Enzyme Inhib Med Chem; 2013 Aug; 28(4):843-52. PubMed ID: 22651800 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, in vitro biological evaluation and in silico studies of certain arylnicotinic acids conjugated with aryl (thio)semicarbazides as a novel class of anti-leishmanial agents. Eldehna WM; Almahli H; Ibrahim TM; Fares M; Al-Warhi T; Boeckler FM; Bekhit AA; Abdel-Aziz HA Eur J Med Chem; 2019 Oct; 179():335-346. PubMed ID: 31260888 [TBL] [Abstract][Full Text] [Related]
14. Antileishmanial agents part-IV: synthesis and antileishmanial activity of novel terpenyl pyrimidines. Chandra N; Ramesh ; Ashutosh ; Goyal N; Suryawanshi SN; Gupta S Eur J Med Chem; 2005 Jun; 40(6):552-6. PubMed ID: 16003841 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species. Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of 2-pyridyl pyrimidines with in vitro antiplasmodial and antileishmanial activity. Musonda CC; Whitlock GA; Witty MJ; Brun R; Kaiser M Bioorg Med Chem Lett; 2009 Jan; 19(2):401-5. PubMed ID: 19091562 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of leishmaniasis part XIII: design and synthesis of novel heteroretinoid-bisbenzylidine ketone hybrids as antileishmanial agents. Tiwari A; Kumar S; Shivahare R; Kant P; Gupta S; Suryawanshi SN Bioorg Med Chem Lett; 2015 Jan; 25(2):410-3. PubMed ID: 25475205 [TBL] [Abstract][Full Text] [Related]
18. Tetrahydrobenzo[h]quinoline derivatives as a novel chemotype for dual antileishmanial-antimalarial activity graced with antitubercular activity: Design, synthesis and biological evaluation. Ibrahim TM; Abada G; Dammann M; Maklad RM; Eldehna WM; Salem R; Abdelaziz MM; El-Domany RA; Bekhit AA; Beockler FM Eur J Med Chem; 2023 Sep; 257():115534. PubMed ID: 37269671 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists. Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033 [TBL] [Abstract][Full Text] [Related]
20. Antileishmanial activity of novel indolyl-coumarin hybrids: Design, synthesis, biological evaluation, molecular docking study and in silico ADME prediction. Sangshetti JN; Kalam Khan FA; Kulkarni AA; Patil RH; Pachpinde AM; Lohar KS; Shinde DB Bioorg Med Chem Lett; 2016 Feb; 26(3):829-835. PubMed ID: 26778149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]